Comparative analysis of care for bronchiolitis requiring observation in pediatric emergency departments after immunoprophylaxis with monoclonal antibodies
Portada nº 274
pdf (Spanish)

Keywords

Bronchiolitis
Respiratory Syncytial Viruses
Antibodies, Monoclonal, Humanized
Emergency Medical Services
Infant

How to Cite

1.
Guerra Díez JL, Matorras Cuevas A, Gomez Arce A. Comparative analysis of care for bronchiolitis requiring observation in pediatric emergency departments after immunoprophylaxis with monoclonal antibodies. Bol Pediatr. 2025;65(274):229-233. doi:10.63788/1jrf3w20

Abstract

Introduction: The implementation of immunoprophylaxis against Respiratory Syncytial Virus (RSV) in infants under 6 months of age has led to a shift in the care burden caused by bronchiolitis in Pediatric Emergency Departments. The aim of this study was to analyze emergency episodes diagnosed as bronchiolitis that required hospital observation before and after the introduction of prophylaxis.

Methods: Episodes included were from children under 24 months of age, diagnosed with bronchiolitis, and admitted to a Short Stay Unit linked to the emergency department. Two periods corresponding to the bronchiolitis epidemic season were analyzed. The variables studied included: age, sex, triage level, length of stay in observation, discharge and microbiological isolation.

Results: There was a 58% reduction in bronchiolitis cases between the two periods and a 66% decrease in those requiring observation. In both periods, most cases occurred in infants under 3 months of age, with a decrease in cases among those aged 3 to 6 months in the second season. No differences were found in observation time or discharge/transfer destination. A significant reduction in RSV detection was observed between the two seasons.

Conclusions: The introduction of RSV prophylaxis has had an impact on the prevalence of RSV-related bronchiolitis in our setting, both in urgent episodes and in the need for observation, with a substantial reduction in absolute numbers and frequency. No significant differences were observed regarding the duration of clinical evolution or the rate of hospital admissions between the seasons.

pdf (Spanish)

References

Benito Fernández J, Paniagua Calzón N. Diagnóstico y tratamiento de la bronquiolitis aguda en Urgencias. Protoc diagn ter pediatr. 2020;1:63-73.

Dalziel SR, Haskell L, O'Brien S, Borland ML, Plint AC, Babl FE, Oakley E. Bronchiolitis. Lancet. 2022; 400(10349):392-406. https://doi.org/10.1016/S0140-6736(22)01016-9

Hon KL, Leung AKC, Wong AHC, Dudi A, Leung KKY. Respiratory Syncytial Virus is the Most Common Causative Agent of Viral Bronchiolitis in Young Children: An Updated Review. Curr Pediatr Rev. 2023;19(2):139-149. https://doi.org/10.2174/1573396318666220810161945

Joseph MM, Edwards A. Acute bronchiolitis: assessment and management in the emergency department. Pediatr Emerg Med Pract. 2019;16(10):1-24.

Cano-Garcinuño A, Praena-Crespo M, Mora-Gandarillas I, Carvajal-Urueña I, Callén-Blecua MT, García-Merino Á, Grupo de Expertos para el Diagnóstico de la Bronquiolitis. Heterogeneidad de criterios en el diagnóstico de bronquiolitis aguda en España. An Pediatr. 2019; 90(2):109-117. https://doi.org/10.1016/j.anpedi.2018.07.004

Ridao Redondo M. Bronquiolitis y bronquitis. Pediatr Integral 2021; XXV (1): 21-28.

Recomendaciones de utilización de nirsevimab frente a virus respiratorio sincitial para la temporada 2023-2024. Grupo de Trabajo utilización de nirsevimab frente a infección por virus respiratorio sincitial de la Ponencia de Programa y Registro de Vacunaciones. Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad, julio 2023. Disponible en: https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/comoTrabajamos/docs/Nirsevimab_2023.pdf

Fujiogi M, Goto T, Yasunaga H, Fujishiro J, Mansbach JM, Camargo CA, et al. Trends in Bronchiolitis Hospitalizations in the United States: 2000-2016. Pediatrics. 2019; 144(6):e20192614. https://doi.org/10.1542/peds.2019-2614

Fernandez A, Mintegi S. Si el triaje carbura, la urgencia funciona. An Pediatr. 2024; 101(6):367-369. https://doi.org/10.1016/j.anpede.2024.10.014

Andina Martínez D, Claret Teruel G, Gijón Mediavilla M, Cámara Otegui A, Baños López L, de Miguel Lavisier B, et al. Impact of universal Respiratory Syncytial Virus prophylaxis in Spain Working Group. Nirsevimab and Acute Bronchiolitis Episodes in Pediatric Emergency Departments. Pediatrics. 2024; 154(4):e2024066584. https://doi.org/10.1542/peds.2024-066584

Vazquez-Lopez P, Rivas-Garcia A, Luaces-Cubells C, Perez-Gonzalez E, Ales-Palmer ML, Cahis-Vela N, et al. Changes in Care in Spanish Pediatric Emergency Departments After the First Immunization With Nirsevimab. Pediatr Emerg Care. 2025; 41(5):365-371. https://doi.org/10.1097/PEC.0000000000003339

Perramon-Malavez A, de Rioja VL, Coma E, Hermosilla E, Fina F, Martínez-Marcos M, Mendioroz J, et al. Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 season. Eur J Pediatr. 2024; 183(12):5181-5189. https://doi.org/10.1007/s00431-024-05779-x

Ares-Gómez S, Mallah N, Santiago-Pérez MI, Pardo-Seco J, Pérez-Martínez O, Otero-Barrós MT, et al. NIRSE-GAL study group. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study. Lancet Infect Dis. 2024; 24(8):817-828. https://doi.org/10.1016/S1473-3099(24)00355-

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright (c) 2025 Boletín de Pediatría